Skip navigation
Skip navigation

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

Kelleher, Anthony D; Puls, Rebekah; Bebbington, Mark; Boyle, David B; Ffrench, Rosemary A; Kent, Stephen J; Kippax, Susan; Purcell, Damian F J; Thomson, Scott; Wand, Handan; Cooper, David A.; Emery, Sean; Munier, Mee Ling; Coupar, Barbara E H; Fielden, Robert; Jaramillo, Angel B; Keoshkerian, Elizabeth; Law, Matthew G; Ramsay, Alistair; Ramshaw, Ian; Satchell, Claudette; Van Bockel, David; Saunders, John B


An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.

CollectionsANU Research Publications
Date published: 2006
Type: Journal article
Source: AIDS: an international monthly journal
DOI: 10.1097/01.aids.0000199819.40079.e9


File Description SizeFormat Image
01_Kelleher_A_randomized,_2006.pdf357.27 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator